Gut microbiome for predicting immune checkpoint blockade-associated adverse events

[1]  Steven M. Blum,et al.  Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses , 2023, Immunological reviews.

[2]  J. Wargo,et al.  Microbiome influencers of checkpoint blockade–associated toxicity , 2023, The Journal of experimental medicine.

[3]  S. Ng,et al.  Faecal microbiome-based machine learning for multi-class disease diagnosis , 2022, Nature Communications.

[4]  C. Huttenhower,et al.  Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin , 2022, Genome Biology.

[5]  B. Tan,et al.  Gut microbiota shed new light on the management of immune‐related adverse events , 2022, Thoracic cancer.

[6]  C. Akdis,et al.  The abundance of Ruminococcus bromii is associated with faecal butyrate levels and atopic dermatitis in infancy , 2022, Allergy.

[7]  Jun Li,et al.  PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation , 2022, Nature Metabolism.

[8]  J. Badger,et al.  Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 , 2022, Nature Medicine.

[9]  Douglas B. Johnson,et al.  Immune-checkpoint inhibitors: long-term implications of toxicity , 2022, Nature Reviews Clinical Oncology.

[10]  Douglas B. Johnson,et al.  Harnessing big data to characterize immune-related adverse events , 2022, Nature Reviews Clinical Oncology.

[11]  N. Okiyama,et al.  Immune-related adverse events in various organs caused by immune checkpoint inhibitors. , 2022, Allergology international : official journal of the Japanese Society of Allergology.

[12]  R. Goldszmid,et al.  Can gut microbes predict efficacy and toxicity of combined immune checkpoint blockade? , 2021, Cancer cell.

[13]  B. Helmink,et al.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2021, Cell.

[14]  R. Sullivan,et al.  Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies , 2021, Nature Reviews Drug Discovery.

[15]  R. Sirera,et al.  Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer , 2021, Cancers.

[16]  A. Mangalam,et al.  Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer , 2021, BMC Cancer.

[17]  M. Tewari,et al.  Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer. , 2021, Trends in cancer.

[18]  J. Bluestone,et al.  Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. , 2021, Trends in immunology.

[19]  K. Wucherpfennig,et al.  Understanding and treating the inflammatory adverse events of cancer immunotherapy , 2021, Cell.

[20]  D. Pinato,et al.  The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer , 2021, Annals of translational medicine.

[21]  N. Ajami,et al.  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial , 2021, Nature Medicine.

[22]  E. Lipson,et al.  A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors , 2021, Clinical Cancer Research.

[23]  G. Weinstock,et al.  Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice , 2021, Nature Microbiology.

[24]  N. Ajami,et al.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients , 2020, Science.

[25]  N. Ajami,et al.  Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade , 2020, Nature Medicine.

[26]  Jing Wang,et al.  A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. , 2020, Cancer discovery.

[27]  Mark M. Davis,et al.  Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade , 2020, Proceedings of the National Academy of Sciences.

[28]  Jun Wang,et al.  Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities , 2020, Frontiers in Immunology.

[29]  Ruixin Zhu,et al.  Identification of microbial markers across populations in early detection of colorectal cancer , 2020, Nature Communications.

[30]  Y. Hosomi,et al.  The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer , 2020, Cancer Immunology Research.

[31]  Hannah L Williams,et al.  Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy , 2020, Cell.

[32]  Gavin M Douglas,et al.  PICRUSt2 for prediction of metagenome functions , 2020, Nature Biotechnology.

[33]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[34]  Liangliang Zhang,et al.  aPCoA: covariate adjusted principal coordinates analysis , 2020, Bioinform..

[35]  He Huang,et al.  Microbial production of vitamin K2: current status and future prospects. , 2020, Biotechnology advances.

[36]  K. Inamura.  Roles of microbiota in response to cancer immunotherapy. , 2020, Seminars in cancer biology.

[37]  Douglas B. Johnson,et al.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[38]  D. Pe’er,et al.  Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies , 2019, Proceedings of the National Academy of Sciences.

[39]  Alberto Martin,et al.  Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities , 2019, Therapeutic advances in gastroenterology.

[40]  Francesco Asnicar,et al.  Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2 , 2019, Nature Biotechnology.

[41]  Takuji Yamada,et al.  Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer , 2019, Nature Medicine.

[42]  D. Bartlett,et al.  Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice , 2019, PloS one.

[43]  H. Shirakawa,et al.  Menaquinone-4 Suppresses Lipopolysaccharide-Induced Inflammation in MG6 Mouse Microglia-Derived Cells by Inhibiting the NF-κB Signaling Pathway , 2019, International journal of molecular sciences.

[44]  Paul Theodor Pyl,et al.  Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer , 2019, Nature Medicine.

[45]  S. Patel,et al.  Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma , 2019, Cancer Immunology, Immunotherapy.

[46]  Marc P. Bonaca,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.

[47]  Luke R. Thompson,et al.  Species-level functional profiling of metagenomes and metatranscriptomes , 2018, Nature Methods.

[48]  J. Cebon,et al.  Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. , 2018, The oncologist.

[49]  S. Baxi,et al.  Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis , 2018, British Medical Journal.

[50]  Mark M. Davis,et al.  Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade , 2017, Proceedings of the National Academy of Sciences.

[51]  J. Wolchok,et al.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  N. Chaput,et al.  Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  L. Siu,et al.  Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  G. Lauwers,et al.  Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies , 2017, The American journal of surgical pathology.

[56]  Paul J. McMurdie,et al.  DADA2: High resolution sample inference from Illumina amplicon data , 2016, Nature Methods.

[57]  C. Huttenhower,et al.  Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis , 2016, Nature Communications.

[58]  J. Wolchok,et al.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[60]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[61]  M. Meyerson,et al.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.

[62]  P. Boyaval,et al.  Quantitative measurement of vitamin K2 (menaquinones) in various fermented dairy products using a reliable high-performance liquid chromatography method. , 2013, Journal of dairy science.

[63]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[64]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[65]  James R. Cole,et al.  The Ribosomal Database Project: improved alignments and new tools for rRNA analysis , 2008, Nucleic Acids Res..

[66]  N. Kishikawa,et al.  Determination of vitamin K homologues by high-performance liquid chromatography with on-line photoreactor and peroxyoxalate chemiluminescence detection. , 2007, Analytica chimica acta.

[67]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.